Allergy Immunotherapy Advances: HDM Market Analysis

DelveInsight’s “Pre-Eclampsia Pipeline Insights 2026” Report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Pre-Eclampsia pipeline landscape. It covers the Pre-Eclampsia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pre-Eclampsia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight’s comprehensive report today! @ Pre-Eclampsia Pipeline Report

Key Takeaways from the Pre-Eclampsia Pipeline Report

• DelveInsight’s Pre-Eclampsia pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Pre-Eclampsia treatment.
• The leading Pre-Eclampsia Companies such as Evergreen Therapeutics, Inc., Comanche Biopharma, and others.
• Promising Pre-Eclampsia Pipeline Therapies such as EG-101, CBP-4888, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pre-Eclampsia Treatment Drugs

The Pre-Eclampsia Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Pre-Eclampsia Pipeline Report also highlights the unmet needs with respect to Pre-Eclampsia.

Pre-Eclampsia Overview

Preeclampsia is a pregnancy-specific hypertensive disorder that usually develops after 20 weeks of gestation and is characterized by new-onset high blood pressure, often accompanied by proteinuria or signs of organ dysfunction. It is part of a spectrum of hypertensive disorders in pregnancy and can progress to severe conditions such as eclampsia or HELLP syndrome if not properly managed. Affecting approximately 2–8% of pregnancies worldwide, preeclampsia is a major cause of maternal and perinatal morbidity and mortality. Early diagnosis and appropriate management are essential to reduce the risk of complications for both the mother and the fetus.

The exact cause of preeclampsia is not fully understood, but it is believed to originate from abnormalities in the placenta. During early pregnancy, blood vessels that supply the placenta may fail to develop or function properly, leading to poor blood flow and impaired oxygen and nutrient delivery. This abnormal placental circulation is thought to trigger changes in the mother’s blood vessels, resulting in high blood pressure and other symptoms. Additionally, several factors such as pre-existing hypertension, diabetes, kidney disease, autoimmune conditions, multiple pregnancies, and obesity can increase the risk of developing preeclampsia.

The pathophysiology of preeclampsia is primarily related to abnormal placental development and uteroplacental ischemia. In early-onset disease, defective trophoblast invasion leads to inadequate remodeling of spiral arteries, resulting in reduced placental perfusion, hypoxia, and ischemia. This triggers the release of factors that cause widespread maternal endothelial dysfunction and vasculopathy, leading to hypertension, proteinuria, and organ damage.

Pre-Eclampsia Emerging Drugs Profile

EG-101: Evergreen Therapeutics, Inc.

EG-101 is an investigational, AI-enabled, small-molecule drug candidate from Evergreen Therapeutics designed to treat preeclampsia. It has received FDA Investigational New Drug (IND) clearance for Phase I trials. EG-101 aims to treat preeclampsia by reducing hypertension and proteinuria, addressing a major unmet need in pregnancy care. In preclinical models, EG-101 demonstrated efficacy in ameliorating hypertension and proteinuria. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Pre-Eclampsia.

CBP-4888: Comanche Biopharma

CBP-4888 is a fixed-dose combination of two chemically-synthesized, lipid-conjugated small interfering ribonucleic acid (siRNAs) duplex oligonucleotides (siRNA-2283 and siRNA-2519) targeting two soluble fms-like tyrosine kinase–1 (sFLT1) mRNA isoforms. In August 2023, the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the investigation of CBP-4888 for the treatment of sFlt1-mediated pre-term preeclampsia. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Pre-Eclampsia.

The Pre-Eclampsia Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pre-Eclampsia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pre-Eclampsia Treatment.
• Pre-Eclampsia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pre-Eclampsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pre-Eclampsia market.

Explore groundbreaking therapies and clinical trials in the Pre-Eclampsia Pipeline @ New Pre-Eclampsia Drugs

Pre-Eclampsia Companies

Evergreen Therapeutics, Inc., Comanche Biopharma, and others.

Pre-Eclampsia Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Pre-Eclampsia Products have been categorized under various Molecule types such as:

• Oligonucleotide
• Peptide
• Small molecule

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Pre-Eclampsia Market Drivers and Barriers

Scope of the Pre-Eclampsia Pipeline Report

• Coverage- Global
• Pre-Eclampsia Companies- Evergreen Therapeutics, Inc., Comanche Biopharma, and others.
• Pre-Eclampsia Pipeline Therapies- EG-101, CBP-4888, and others.
• Pre-Eclampsia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pre-Eclampsia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Pre-Eclampsia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Pre-Eclampsia Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Pre-Eclampsia: Overview
4. Pipeline Therapeutics
5. Comparative Analysis
6. Therapeutic Assessment
7. Pre-Eclampsia – DelveInsight’s Analytical Perspective
8. Late Stage Products (Phase III)
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Preclinical and Discovery Stage Products
12. Inactive Products
13. Pre-Eclampsia Key Companies
14. Pre-Eclampsia Key Products
15. Pre-Eclampsia – Unmet Needs
16. Pre-Eclampsia – Market Drivers and Barriers
17. Pre-Eclampsia – Future Perspectives and Conclusion
18. Pre-Eclampsia Analyst Views
19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com 

DelveInsight’s “Geographic Atrophy Pipeline Insights 2026” Report provides comprehensive insights about 23+ companies and 25+ pipeline drugs in Geographic Atrophy pipeline landscape. It covers the Geographic Atrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Geographic Atrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight’s comprehensive report today! @ Geographic Atrophy Pipeline Report

Key Takeaways from the Geographic Atrophy Pipeline Report

• In January 2026, The US Food and Drug Administration (FDA) has awarded Fast Track Designation to Complement Therapeutics’ lead gene therapy candidate, CTx001, for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD). Earlier, in October 2025, the FDA cleared the company’s Investigational New Drug (IND) application for CTx001, enabling the initiation of the Phase 1/2 Opti-GAIN study.
• In October 2025, Astellas Pharma Inc. announced the initial findings from the open-label extension phase of the Phase 3 GATHER2 trial, showing that monthly treatment with IZERVAY in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) continued to slow GA lesion progression for up to 3.5 years. The data also highlighted that earlier treatment initiation provided greater preservation of retinal tissue. IZERVAY demonstrated a favorable safety profile, with no reported cases of retinal vasculitis or occlusive vasculitis. These results, supporting the cumulative long-term benefit of IZERVAY, were presented during Retina Subspeciality Day at the American Academy of Ophthalmology 2025 Annual Meeting in Orlando. 
• DelveInsight’s Geographic Atrophy pipeline report depicts a robust space with 23+ active players working to develop 25+ pipeline therapies for Geographic Atrophy treatment.
• The leading Geographic Atrophy Companies such as IVERIC bio, Ionis Pharmaceuticals, and others.
• Promising Geographic Atrophy Pipeline Therapies such as Zimura, IONIS-FB-LRx, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Geographic Atrophy Treatment Drugs

The Geographic Atrophy Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Geographic Atrophy Pipeline Report also highlights the unmet needs with respect to Geographic Atrophy.

Geographic Atrophy Overview

Geographic atrophy (GA) is a chronic progressive degeneration of the macula, as part of late-stage age-related macular degeneration (AMD). The disease is characterized by localized sharply demarcated atrophy of outer retinal tissue, retinal pigment epithelium and choriocapillaris. It starts typically in the perifoveal region and expands to involve the fovea with time, leading to central scotomas and permanent loss of visual acuity. It is bilateral in most cases. Over 8 million people are affected worldwide with GA, approximately 20% of all individuals with AMD.

The incidence of GA is expected to rise as the age-burden of developed countries is increasing. Several risk factors have been noted by several studies. The most pronounced risk factor is increasing age and family history of AMD. Smoking history increases the risk of GA significantly. Both active smokers, but also former smokers are at greater risk of developing geographic atrophy.

Geographic Atrophy Emerging Drugs Profile

IONIS-FB-LRx: Ionis Pharmaceuticals

IONIS-FB-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration (AMD). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in capillaries in the eye. The drug is currently in clinical trial evaluation to treat Geographic Atrophy.

Zimura: IVERIC bio

Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells. This potential mechanism is the rationale for Zimura as a potential therapy for geographic atrophy secondary to age-related macular degeneration. The drug is currently in Phase III stage of clinical trial evaluation to treat Geographic Atrophy.

The Geographic Atrophy Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Geographic Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Geographic Atrophy Treatment.
• Geographic Atrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Geographic Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Geographic Atrophy market.

Explore groundbreaking therapies and clinical trials in the Geographic Atrophy Pipeline @ New Geographic Atrophy Drugs

Geographic Atrophy Companies

IVERIC bio, Ionis Pharmaceuticals, and others.

Geographic Atrophy Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Geographic Atrophy Products have been categorized under various Molecule types such as:

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Geographic Atrophy Market Drivers and Barriers

Scope of the Geographic Atrophy Pipeline Report

• Coverage- Global
• Geographic Atrophy Companies- IVERIC bio, Ionis Pharmaceuticals, and others.
• Geographic Atrophy Pipeline Therapies- Zimura, IONIS-FB-LRx, and others.
• Geographic Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Geographic Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Geographic Atrophy Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Geographic Atrophy Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Geographic Atrophy: Overview
4. Pipeline Therapeutics
5. Comparative Analysis
6. Therapeutic Assessment
7. Geographic Atrophy – DelveInsight’s Analytical Perspective
8. Late Stage Products (Phase III)
9. Mid Stage Products (Phase II)
10. Inactive Products
11. Geographic Atrophy Key Companies
12. Geographic Atrophy Key Products
13. Geographic Atrophy – Unmet Needs
14. Geographic Atrophy – Market Drivers and Barriers
15. Geographic Atrophy – Future Perspectives and Conclusion
16. Geographic 
17. Atrophy Analyst Views
18. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Parkinson’s Disease Pipeline Insights 2026” Report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in the Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight’s comprehensive report today! @ Parkinson’s Disease Pipeline Report

Key Takeaways from the Parkinson’s Disease Pipeline Report

• DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 150+ active players working to develop 200+ pipeline therapies for Parkinson’s Disease treatment.
• The leading Parkinson’s Disease Companies such as Roche, Prothena Biosciences, Annovis Bio, Neuron23, Ventyx Biosciences, Aspen Neuroscience, Lundbeck, Biohaven Pharmaceuticals, Neuraly Inc, FAScinate Therapeutics, Cerevance, Jazz Pharmaceuticals, Sanofi, Eli Lilly and Company, and others.
• Promising Parkinson’s Disease Pipeline Therapies such as Prasinezumab, Buntanetap, NEU 411, VTX3232, ANPD001, Lu AF28996, NLY01, CVN424, Mesdopetam, BHV-8000, ENT-01, JZP385, LY4006896, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Parkinson’s Disease Treatment Drugs

The Parkinson’s Disease Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Parkinson’s Disease Pipeline Report also highlights the unmet needs with respect to Parkinson’s Disease.

Parkinson’s Disease Overview

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement and coordination. It results from the gradual loss of dopamine-producing neurons in the brain, leading to characteristic motor and non-motor symptoms. The disease typically develops in older adults and progresses slowly, with symptoms worsening over time. Although not curable, available treatments can effectively manage symptoms and improve quality of life.

Parkinson’s disease is caused by a combination of genetic and environmental factors that lead to progressive neuronal damage. Advancing age is the strongest risk factor, while inherited mutations in genes such as SNCA, LRRK2, PARK2, PINK1, and DJ-1 contribute to familial forms of the disease. The disease is characterized by degeneration of dopamine-producing neurons in the substantia nigra pars compacta, resulting in reduced dopamine levels in the nigrostriatal pathway. Additionally, abnormal aggregation of misfolded α-synuclein protein leads to the formation of Lewy bodies, contributing to neuronal dysfunction, inflammation, and progressive neurodegeneration.

Parkinson’s disease presents with hallmark motor symptoms such as resting tremor, bradykinesia, muscular rigidity, and postural instability. Non-motor manifestations are common and include depression, anxiety, cognitive impairment, sleep disturbances, autonomic dysfunction, fatigue, and loss of smell.

Parkinson’s Disease Emerging Drugs Profile

Prasinezumab: Roche/Prothena Biosciences

Prasinezumab is an investigational monoclonal antibody designed to bind aggregated alpha-synuclein and thereby reduce neuronal toxicity. By reducing the build-up of alpha-synuclein protein in the brain, prasinezumab can potentially prevent further accumulation and spreading between cells, which may slow progression of the disease. The safety database for prasinezumab consists of data from more than 900 Parkinson’s disease study participants that have been treated with the investigational medicine, of which more than 750 remain in open label treatment with over 500 treated for 1.5-5 years. The drug is currently in Phase III stage of clinical trial evaluation to treat Parkinson’s disease.

Buntanetap: Annovis Bio

Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in Parkinson’s disease and other neurodegenerative diseases, thereby restoring brain function and improving the quality of life for patients. The drug is currently in Phase III stage of its clinical development for the treatment of patients with Parkinson’s disease.

NEU 411: Neuron23

NEU‑411 is an orally available, brain-penetrant small-molecule inhibitor of the kinase LRRK2, being developed by Neuron23, Inc. for Parkinson’s disease. It is designed for the subset of patients with LRRK2-driven PD whether through LRRK2 mutations or predictive SNPs where over activity of LRRK2 is believed to contribute to disease progression. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of Parkinson’s disease.

VTX3232: Ventyx Biosciences

VTX3232 is an oral, brain-penetrant inhibitor of the NLRP3 inflammasome, developed to target neuroinflammation in Parkinson’s disease by reducing harmful signaling from microglial activation. It crosses the blood–brain barrier, maintains plasma and cerebrospinal fluid concentrations above the inhibitory threshold for NLRP3, and thereby aims to not only ease motor/non-motor symptoms but modify underlying disease progression. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Parkinson’s disease.

ANPD001: Aspen Neuroscience

ANPD001, developed by Aspen Neuroscience, is an investigational autologous cell-therapy for Parkinson’s disease that uses a patient’s own skin cells reprogrammed into induced pluripotent stem cells (iPSCs), then differentiated into dopaminergic neuronal precursor cells (DANPCs) for implantation. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Parkinson’s disease.

Lu AF28996: Lundbeck

Lu AF28996 is an investigational small-molecule therapy developed by H. Lundbeck A/S for the treatment of Parkinson’s disease. It is designed as a dual dopamine D1 and D2 receptor agonist, providing concerted stimulation of both receptor subtypes to restore dopaminergic signaling and improve motor control in patients with Parkinson’s disease. This mechanism of action aims to compensate for dopamine deficiency in the nigrostriatal pathway, thereby alleviating motor symptoms such as bradykinesia and rigidity. Lu AF28996 is formulated for oral administration, typically delivered as a capsule taken once daily. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Parkinson’s disease.

The Parkinson’s Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s Disease Treatment.
• Parkinson’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Parkinson’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson’s Disease market.

Explore groundbreaking therapies and clinical trials in the Parkinson’s Disease Pipeline @ New Parkinson’s Disease Drugs

Parkinson’s Disease Companies

Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc, FAScinate Therapeutics, Cerevance, Hillhurst Biopharmaceuticals, Inc., Endurance Bio, Enterin Inc., Jazz Pharmaceuticals plc, Mthera Pharma Co., Ltd., TrueBinding, IRLAB, Annovis Bio Inc, Neuron23, Forest Hills Lab, Ventyx Biosciences, HanAll Biopharma, Lundbeck, Sanofi, ABL Bio, Contera Pharma, Eli Lilly and Company, Asceneuron SA, Allyx Therapeutics, Inc., Ventus Therapeutics, and others.

Parkinson’s Disease Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Parkinson’s Disease Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal Antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Parkinson’s Disease Market Drivers and Barriers

Scope of the Parkinson’s Disease Pipeline Report

• Coverage- Global
• Parkinson’s Disease Companies- Roche, Prothena Biosciences, Annovis Bio, Neuron23, Ventyx Biosciences, Aspen Neuroscience, Lundbeck, Biohaven Pharmaceuticals, Jazz Pharmaceuticals, Sanofi, Eli Lilly and Company, and others.
• Parkinson’s Disease Pipeline Therapies- Prasinezumab, Buntanetap, NEU 411, VTX3232, ANPD001, Lu AF28996, NLY01, CVN424, Mesdopetam, BHV-8000, ENT-01, JZP385, LY4006896, and others.
• Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Parkinson’s Disease Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Parkinson’s Disease Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Parkinson’s Disease: Overview
4. Comparative Analysis
5. Therapeutic Assessment
6. Parkinson’s Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. Preclinical and Discovery Stage Products
11. Inactive Products
12. Parkinson’s Disease Key Companies
13. Parkinson’s Disease Key Products
14. Parkinson’s Disease – Unmet Needs
15. Parkinson’s Disease – Market Drivers and Barriers
16. Parkinson’s Disease – Future Perspectives and Conclusion
17. Parkinson’s Disease Analyst Views
18. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Exosomes Pipeline Insights 2026” Report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Exosomes pipeline landscape. It covers the Exosomes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight’s comprehensive report today! @ Exosomes Pipeline Report

Key Takeaways from the Exosomes Pipeline Report

• DelveInsight’s Exosomes pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Exosomes applications.
• The leading Exosomes Companies such as Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd., and others.
• Promising Exosomes Pipeline Therapies such as CAP-1002, Debamestrocel, AGLE-102, EXOB-001, RioMSK001, SNE-101, SOB 100, MVR-EX101, ILB 202, STM-01, MDX-101, EViv, BRE-NA01, SBI-101, EXOSTEO01, Exo–101, COYA 201, VZT-PEV, ExoPTEN therapy, ExoVeris, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs

The Exosomes Pipeline Report provides overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Exosomes Pipeline Report also highlights the unmet needs with respect to Exosomes applications.

Exosomes Overview

Exosomes are small extracellular vesicles (≈40–160 nm) released by most cell types through the fusion of multivesicular bodies with the plasma membrane, which liberates intraluminal vesicles into the extracellular space. They are widely present in biological fluids such as blood, urine, breast milk, and semen, and can be taken up by distant cells. Through the transfer of bioactive cargo, exosomes play a crucial role in cell–cell communication and can influence disease progression. Their contents including proteins, lipids, nucleic acids, amino acids, and metabolites reflect their cell of origin and are shaped during their biogenesis in the endosomal pathway.

Exosomes are formed through a double invagination process of the plasma membrane, leading to the creation of multivesicular bodies (MVBs) that contain intraluminal vesicles (ILVs), which are later released as exosomes upon fusion with the plasma membrane. Their biogenesis is tightly regulated by proteins such as ESCRT complexes, Rab GTPases, ALIX, and tetraspanins, which facilitate cargo sorting, membrane budding, and vesicle release. Exosomes carry diverse biomolecules including DNA, RNA, proteins, lipids, and metabolites reflecting their cell of origin and functional state.

Exosomes are being widely investigated for both diagnostic and therapeutic applications due to their complex molecular cargo and natural role in intercellular communication. As they are present in nearly all biological fluids, they offer a minimally invasive “liquid biopsy” approach for disease detection and monitoring across conditions such as cancer, cardiovascular, neurological, and organ-specific diseases. Therapeutically, exosomes exhibit excellent biocompatibility, low immunogenicity, and efficient biodistribution, enabling targeted delivery of functional biomolecules to diseased cells. They can also serve as natural drug delivery vehicles, capable of crossing biological barriers like the blood–brain barrier and delivering payloads such as RNA or drugs with reduced toxicity.

Exosomes Emerging Drugs Profile

CAP-1002: Capricor Therapeutics

Capricor’s CAP-1002 consists of cardiosphere-derived cells (CDCs), a type of cardiac progenitor cell originally discovered in the laboratory of its scientific founder, Eduardo Marbán. These CDCs have been extensively studied, with over 100 peer-reviewed publications and clinical administration in more than 200 patients across multiple trials. CAP-1002 works by releasing exosomes, small vesicles that influence immune responses and promote tissue repair. These exosomes are primarily taken up by macrophages and T cells, triggering regenerative processes and modulating immune activity. The therapy is currently in the registration stage for the treatment of Duchenne Muscular Dystrophy.

Debamestrocel: BrainStorm Cell Therapeutics

Debamestrocel (NurOwn) consists of autologous bone marrow–derived mesenchymal stem cells (MSCs) that are cultured to secrete elevated levels of neurotrophic factors, supporting neuronal survival and repair. These MSC-NTF cells combine the immunomodulatory effects of MSCs with enhanced neurotrophic activity, partly mediated through exosome-based delivery of factors such as GDNF. The therapy is manufactured from a patient’s own MSCs, expanded and differentiated ex vivo without genetic modification, and then re-administered. It is currently in Phase III development for the treatment of Amyotrophic Lateral Sclerosis, with additional programs in multiple neurological disorders at earlier stages.

AGLE-102: Aegle Therapeutics

AGLE-102 is an allogeneic extracellular vesicle (EV) therapy derived from mesenchymal stem cells obtained from healthy donors. It consists of MSC-derived vesicles that deliver proteins, genetic material, and regenerative factors to support repair in damaged tissues. The therapy is currently in Phase I/II development for the treatment of burns and Epidermolysis Bullosa Dystrophica, and is also being explored at the preclinical stage for Graft-versus-Host Disease.

RioMSK001: RION

RioMSK001 is an innovative therapeutic candidate developed by Rion for musculoskeletal disorders. It is designed to address degenerative joint conditions with a focus on improving function and reducing disease burden. According to the company’s pipeline, the therapy is currently in early clinical evaluation. It is in Phase I development for the treatment of Knee Osteoarthritis.

HEPATOSOME: ExoStemTech

HEPATOSOME is an investigational therapy being developed by ExoStemTech. It is designed as a novel approach targeting liver-related disorders through advanced therapeutic mechanisms. The candidate is currently undergoing early-stage research and evaluation. At present, it is in preclinical development for the treatment of Liver Fibrosis.

The Exosomes Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies utilizing Exosomes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes-based Treatment.
• Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.

Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline @ New Exosomes Drugs

Exosomes Companies

Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd., and others.

Exosomes Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Exosomes Products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal Antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Exosomes Market Drivers and Barriers

Scope of the Exosomes Pipeline Report

• Coverage- Global
• Exosomes Companies- Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd., and others.
• Exosomes Pipeline Therapies- CAP-1002, Debamestrocel, AGLE-102, EXOB-001, RioMSK001, SNE-101, SOB 100, MVR-EX101, ILB 202, STM-01, MDX-101, EViv, BRE-NA01, SBI-101, EXOSTEO01, Exo–101, COYA 201, VZT-PEV, ExoPTEN therapy, ExoVeris, and others.
• Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Registration

Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Exosomes: Overview
4. Pipeline Therapeutics
5. Comparative Analysis
6. Therapeutic Assessment
7. Exosomes – DelveInsight’s Analytical Perspective
8. Late Stage Products (Phase III)
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Preclinical and Discovery Stage Products
12. Inactive Products
13. Exosomes Key Companies
14. Exosomes Key Products
15. Exosomes – Unmet Needs
16. Exosomes – Market Drivers and Barriers
17. Exosomes – Future Perspectives and Conclusion
18. Exosomes Analyst Views
19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Sarcoidosis Pipeline Insights 2026” Report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Sarcoidosis pipeline landscape. It covers the Sarcoidosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcoidosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight’s comprehensive report today! @ https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Key Takeaways from the Sarcoidosis Pipeline Report

• In September 2025, Shares of aTyr Pharma dropped by more than 80% after its Phase III clinical trial in pulmonary sarcoidosis did not achieve its primary endpoint. In the EFZO-FIT trial, Efzofitimod failed to demonstrate an improvement in mean daily oral corticosteroid (OCS) dose at Week 48. Patients receiving 5.0 mg/kg efzofitimod experienced an average OCS dose reduction of 2.79 mg, compared with a 3.52 mg reduction observed in the placebo group.
• In May 2025, Prednisone was commonly recommended as the first-line therapy for pulmonary sarcoidosis, although its use is often associated with several undesirable side effects. New findings presented at ATS 2025 suggest that Methotrexate may serve as an effective alternative. Researchers reported that methotrexate demonstrated comparable disease control to prednisone while potentially offering a lower risk of side effects.
• In March 2025, aTyr Pharma announced a fourth favorable Data Safety Monitoring Board (DSMB) assessment for its Phase III EFZO-FIT trial evaluating efzofitimod in pulmonary sarcoidosis. The DSMB found no safety issues and advised that the study proceed as planned, with topline data anticipated in the third quarter of 2025.
• In March 2025, Xentria announced that enrollment has been completed for its Phase Ia/IIb XTMAB16 clinical trial in pulmonary sarcoidosis, with 39 patients recruited across four countries. The randomized, placebo-controlled, dose-ranging study exceeded its original enrollment goals.
• DelveInsight’s Sarcoidosis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Sarcoidosis treatment.
• The leading Sarcoidosis Companies such as Relief Therapeutics, aTyr Pharma, Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, and others.
• Promising Sarcoidosis Pipeline Therapies such as Efzofitimod, RLF-100, Abrocitinib, Inhaled Treprostinil, XTMAB-16, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Sarcoidosis Treatment Drugs

The Sarcoidosis Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Sarcoidosis Pipeline Report also highlights the unmet needs with respect to Sarcoidosis.

Sarcoidosis Overview

The multisystem illness sarcoidosis, whose cause is uncertain, is typified by non-caseating granulomas in the organs. This disease primarily affects young individuals and is characterized by bilateral hilar lymphadenopathy and reticular opacities in the lungs.

Sarcoidosis Emerging Drugs Profile

Efzofitimod: aTyr Pharma

Efzofitimod is an investigational therapeutic candidate developed by aTyr Pharma for the treatment of pulmonary sarcoidosis. The drug is currently in Phase III stage of clinical trial evaluation to treat Sarcoidosis.

RLF-100: Relief Therapeutics

RLF-100 is an investigational therapeutic candidate developed by Relief Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

Abrocitinib: Pfizer

Abrocitinib is an investigational therapeutic candidate developed by Pfizer for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

Inhaled Treprostinil: United Therapeutics

Inhaled Treprostinil is an investigational therapeutic candidate developed by United Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

XTMAB-16: Xentria, Inc.

XTMAB-16 is an investigational therapeutic candidate developed by Xentria, Inc. for the treatment of pulmonary sarcoidosis. The drug is currently in Phase Ia/IIb clinical trial evaluation to treat Sarcoidosis.

CMK389: Novartis

CMK389 is an investigational therapeutic candidate developed by Novartis for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

Namilumab: Kinevant Sciences GmbH

Namilumab is an investigational therapeutic candidate developed by Kinevant Sciences GmbH for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

FP-020: Foresee Pharmaceuticals

FP-020 is an investigational therapeutic candidate developed by Foresee Pharmaceuticals for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

LAM001: AI Therapeutics

LAM001 is an investigational therapeutic candidate developed by AI Therapeutics for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

OATD-01: Molecure

OATD-01 is an investigational therapeutic candidate developed by Molecure for the treatment of Sarcoidosis. The drug is currently in clinical trial evaluation to treat Sarcoidosis.

The Sarcoidosis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcoidosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcoidosis Treatment.
• Sarcoidosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcoidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcoidosis market.

Explore groundbreaking therapies and clinical trials in the Sarcoidosis Pipeline @ New Sarcoidosis Drugs

Sarcoidosis Companies

Relief Therapeutics, aTyr Pharma, Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, and others.

Sarcoidosis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous

Sarcoidosis Products have been categorized under various Molecule types such as:

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Sarcoidosis Market Drivers and Barriers

Scope of the Sarcoidosis Pipeline Report

• Coverage- Global
• Sarcoidosis Companies- Relief Therapeutics, aTyr Pharma, Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharmaceutical Co., Ltd, Novartis, Kinevant Sciences GmbH, Foresee Pharmaceuticals, AI Therapeutics, Molecure, and others.
• Sarcoidosis Pipeline Therapies- Efzofitimod, RLF-100, Abrocitinib, Inhaled Treprostinil, XTMAB-16, CMK389, Namilumab, FP-020, LAM001, OATD-01, and others.
• Sarcoidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sarcoidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Sarcoidosis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Sarcoidosis Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Sarcoidosis: Overview
4. Pipeline Therapeutics
5. Comparative Analysis
6. Therapeutic Assessment
7. Sarcoidosis – DelveInsight’s Analytical Perspective
8. Late Stage Products (Phase III)
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. Preclinical Stage Products
12. Inactive Products
13. Sarcoidosis Key Companies
14. Sarcoidosis Key Products
15. Sarcoidosis – Unmet Needs
16. Sarcoidosis – Market Drivers and Barriers
17. Sarcoidosis – Future Perspectives and Conclusion
18. Sarcoidosis Analyst Views
19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

The Celiac Disease market is poised for steady growth over the coming years as pharmaceutical companies invest in novel treatments aimed at improving the quality of life for patients living with this chronic autoimmune condition. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Celiac Disease market dynamics.

DelveInsight’s “Celiac Disease Treatment Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Celiac Disease Market Forecast

Some of the key facts of the Celiac Disease Market Report

• In May 2025, Teva Pharmaceutical announced FDA Fast Track designation for TEV-53408, an anti-IL-15 antibody in Phase 2a trials for treating adults with celiac disease on a gluten-free diet
• In July 2024, The Beyond Celiac Coalition engaged with the FDA to adopt a patient-centric approach to therapeutic trials, aiming to enhance patient involvement while ensuring scientific rigor in the development of new treatments
• The Celiac Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2024, a landmark study identified that ZED1227, an investigational drug, successfully prevented gluten-induced intestinal damage by targeting specific molecular mechanisms, marking a significant step forward in celiac disease therapy
• Celiac Disease affects approximately 1 in 100 people worldwide, yet only about 30% are properly diagnosed
• The disease predominantly impacts females and is most commonly diagnosed in individuals aged 19-39
• Despite adherence to a gluten-free diet, approximately 5% of Celiac Disease Patients continue to suffer from symptoms, underscoring the urgent need for advanced treatment options
• Latiglutenase, Ordesekimab, TAK-101, and ZED1227 are the most anticipated emerging products for the Celiac Disease treatment, that are in the mid or late phase of clinical trials awaiting approval
• Key Celiac Disease Companies: Entero Therapeutics, Amgen/Provention Bio, Takeda, Sanofi, and others
• Key Celiac Disease Therapies: Latiglutenase, Ordesekimab, TAK-101, TAK-227, ZED1227, and others
• The Celiac Disease epidemiology based on gender analyzed that approximately 60% of diagnosed cases in Germany are female

Request a sample for the Celiac Disease Market Report

Celiac Disease Overview

Celiac disease is a chronic autoimmune disorder driven by an inappropriate immune response to gluten, a protein in wheat, barley, and rye, in genetically predisposed individuals. The disease primarily targets the small intestine, causing inflammation and mucosal damage, leading to a spectrum of gastrointestinal symptoms like chronic diarrhea, abdominal pain, and malabsorption, as well as extraintestinal issues such as anemia, osteoporosis, and neurological disturbances.

Celiac Disease Epidemiology Segmentation

The Celiac Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Total Celiac Disease Prevalent Population
• Total Celiac Disease Diagnosed Prevalent Population
• Celiac Disease Gender-specific Diagnosed Prevalent Population
• Celiac Disease Type-specific Diagnosed Prevalent Population
• Celiac Disease Age-specific Distribution

Download the report to understand which factors are driving Celiac Disease epidemiology trends @ Celiac Disease Epidemiological Insights

Celiac Disease Market

The dynamics of the Celiac Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Latiglutenase, Ordesekimab, TAK-101, and others during the forecasted period 2020-2034.

Celiac Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Celiac Disease Therapies and Key Companies

• Latiglutenase: Entero Therapeutics
• Ordesekimab: Amgen/Provention Bio
• TAK-101: Takeda
• TAK-227: Takeda
• ZED1227: Dr. Falk Pharma

To know more about Celiac Disease treatment, visit @ Celiac Disease Companies

Celiac Disease Market Drivers

• Rising awareness about celiac disease leading to improved diagnosis rates
• Advancements in targeted therapies and novel treatment options enhancing patient outcomes
• Growing celiac disease prevalence globally, driving demand for effective treatments
• Increasing patient dissatisfaction with gluten-free diet alone, creating demand for pharmacological interventions
• Enhanced understanding of disease pathophysiology enabling development of mechanism-based therapies
• Regulatory support through Fast Track Designations accelerating drug development timelines

Celiac Disease Market Barriers

• Limited availability of approved pharmacologic treatments, with gluten-free diet remaining the only effective option
• High treatment costs for emerging therapies, restricting access in various regions
• Challenges in early diagnosis due to varied clinical presentations and low diagnosis rates (only 30% properly diagnosed)
• Regulatory hurdles and long approval timelines for new therapies
• Patient adherence challenges with lifelong dietary restrictions
• Approximately 5% of patients remain symptomatic despite strict gluten-free diet adherence

Scope of the Celiac Disease Market Report

• Coverage: 7MM 
• Study Period: 2020-2034
• Key Celiac Disease Companies: Entero Therapeutics, Amgen/Provention Bio, Takeda, Sanofi, and others
• Key Celiac Disease Therapies: Latiglutenase, Ordesekimab, TAK-101, TAK-227, ZED1227, and others
• Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
• Celiac Disease Market Dynamics: Celiac Disease market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Celiac Disease Market Access and Reimbursement

Table of Content

1. Key Insights
2. Report Introduction
3. Executive Summary of Celiac Disease
4. Key Events
5. Celiac Disease and Market Forecast Methodology
6. Celiac Disease Market Overview at a Glance
7. Disease Background and Overview: Celiac Disease
8. Treatment and Management
9. Epidemiology and Patient Population of Celiac Disease in the 7MM
10. Patient Journey
11. Key Endpoints in Celiac Disease
12. Emerging Therapies
13. Celiac Disease: Seven Major Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.

Contact Information

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Autism Spectrum Disorder Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Autism Spectrum Disorder, historical and forecasted epidemiology as well as the Autism Spectrum Disorder market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Autism Spectrum Disorder Market with DelveInsight’s In-Depth Report @ Autism Spectrum Disorder Market Size

Key Takeaways from the Autism Spectrum Disorder Market Report

• In Feb 2025, DeFloria, Inc. announced that the FDA completed its review of the Investigational New Drug (IND) application for AJA001, an orally delivered, multi-cannabinoid botanical drug for treating symptoms of autism spectrum disorder (ASD). The company plans to proceed with its Phase 2 clinical trial, set to begin by mid-2025.
• In January 2025, the FDA granted Orphan Drug Designation (ODD) to Capsida Biotherapeutics for CAP-002, a first-in-class gene therapy for STXBP1 disorder, developed in collaboration with Dr. Mingshan Xue at Texas Children’s Duncan Neurological Research Institute.
• As per the analysis, about 1 in 44 children, aged 8 years, have been identified with autism spectrum disorder in the US. Boys were found to be four times more likely to be identified with autism spectrum disorder than girls.
• Various sources estimate that around 700,000 people in the UK have a diagnosis of autism, with one in 100 children in the UK having autism spectrum disorder.
• As per analysis, in Germany, children from 6 to 11 years of age showed the highest prevalence, estimated at around 6.0 per 1000.
• According to the analysis, in Japan, the adjusted autism spectrum disorder prevalence was around 3%, with a male-to-female ratio of 2.2:1. Sex differences in behavior, or the presentation of autistic symptoms and co-morbid intellectual disability may contribute to the male bias in diagnoses.
• In 2022, the United States held a significant share of the overall 7MM Autism Spectrum Disorder market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments.
• The leading Autism Spectrum Disorder Companies such as Aardvark Therapeutics, Inc., Otsuka Pharmaceutical, H. Lundbeck A/S, Jazz Pharmaceuticals, MapLight Therapeutics, Vanda Pharmaceuticals, ACADIA Pharmaceuticals Inc., AbbVie, Axial Therapeutics, Inc., Hoffmann-La Roche, Yamo Pharmaceuticals LLC, Janssen Pharmaceuticals, Neurim Pharmaceuticals, Flynn Pharma, and others.
• Promising Autism Spectrum Disorder Therapies such as ML-004, RG7816 (alogabat/RO7017773), AB-2004, L1-79, AJA001, BA-102, CAP-002, radiprodil, and others.

Stay ahead in the Autism Spectrum Disorder Therapeutics Market with DelveInsight’s Strategic Report @ Autism Spectrum Disorder Market Outlook

Autism Spectrum Disorder Epidemiology Segmentation in the 7MM

• Total Diagnosed Prevalent Cases of Autism Spectrum Disorder
• Gender-specific Diagnosed Prevalent Cases of Autism Spectrum Disorder
• Age-specific Diagnosed Prevalent Cases of Autism Spectrum Disorder
• Total Treated Cases of Autism Spectrum Disorder

Download the report to understand which factors are driving Autism Spectrum Disorder Epidemiology trends @ Autism Spectrum Disorder Prevalence

Marketed Autism Spectrum Disorder Therapies

• RISPERDAL (risperidone): Janssen Pharmaceuticals RISPERDAL (risperidone) is the first US FDA-approved medication for the treatment of symptoms associated with autism spectrum disorder in children and adolescents, including aggressive behavior, deliberate self-injury, and temper tantrums. Risperidone is available in various formulations, including oral tablets and oral solutions. In October 2006, it was approved by the US FDA for the symptomatic treatment of irritability in autistic children and adolescents.
• ABILIFY (aripiprazole): Otsuka Pharmaceutical ABILIFY (aripiprazole) is US FDA-approved for the treatment of irritability in children and adolescents with autism spectrum disorder. The medication helps manage behavioral symptoms and improve daily functioning in patients with ASD.
• SLENYTO (melatonin): Neurim Pharmaceuticals/Flynn Pharma SLENYTO is the first and only pharmacotherapy that is approved for the treatment of insomnia in children with autism spectrum disorder. SLENYTO is a prolonged-release melatonin minitablet developed specifically for the treatment of insomnia in these children, addressing their specific needs. The active ingredient in SLENYTO is melatonin which is a hormone produced by the body. SLENYTO is available in two dosage forms, 1 mg and 5 mg prolonged-release tablets. The activity of melatonin at the melatonin receptors (MT1, MT2, and MT3) is believed to contribute to its sleep-promoting properties.

Emerging Autism Spectrum Disorder Therapies

• ML-004: MapLight Therapeutics ML-004 is MapLight’s lead clinical compound. Its selective pharmacological properties make it a highly specific therapy with limited side effects. It is a 5-HT1B receptor agonist. The company is developing ML-004 for multiple indications, including sociability and irritability in autism spectrum disorder and agitation and aggression in Alzheimer’s disease. Currently, the drug is being evaluated in a Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety profile of ML-004 in up to 150 adults and adolescents with autism spectrum disorder.
• RG7816 (alogabat/RO7017773): Hoffmann-La Roche RO7017773 is a small molecule highly selective positive allosteric modulator of the GABAA α5 receptor, which is expressed in key brain regions for autism spectrum disorder. Currently, the drug is being evaluated in a Phase II, multicenter, randomized, double-blind, study to investigate the efficacy, safety, and tolerability of RO7017773 in participants aged 15-45 years with autism spectrum disorder.
• AB-2004: Axial Therapeutics AB-2004 is an investigational therapy that targets the microbiome-gut-brain axis and its role in co-occurring conditions associated with autism spectrum disorder. AB-2004 is a gut-targeted, molecular therapeutic, which means it is designed to work in the gut only and does not enter other bodily tissues. Currently, the drug is being evaluated in a Phase IIb, randomized, double-blind, placebo-controlled study in a 13 to 17-year-old autism spectrum disorder population.

To know more about Autism Spectrum Disorder treatment guidelines, visit @ Autism Spectrum Disorder Treatment Market Landscape

Autism Spectrum Disorder Therapies and Companies

• ML-004: MapLight Therapeutics
• RG7816 (alogabat/RO7017773): Hoffmann-La Roche
• AB-2004: Axial Therapeutics, Inc.
• L1-79: Yamo Pharmaceuticals LLC
• AJA001: DeFloria, Inc.
• BA-102: NeuroNOS/Beyond Air
• CAP-002: Capsida Biotherapeutics
• radiprodil: GRIN Therapeutics, Inc.
• RISPERDAL (risperidone): Janssen Pharmaceuticals
• ABILIFY (aripiprazole): Otsuka Pharmaceutical
• SLENYTO (melatonin): Neurim Pharmaceuticals/Flynn Pharma

Autism Spectrum Disorder Market Dynamics The Autism Spectrum Disorder market dynamics have undergone significant changes over the years. Firstly, the aging population and increasing prevalence is a significant driver. The rising global prevalence of Autism Spectrum Disorder is a major factor driving market growth, leading to higher demand for diagnostic services, therapies, and long-term care solutions. Additionally, growing awareness among parents, educators, and healthcare professionals has improved early screening and diagnosis, enabling timely intervention and expanding the patient population seeking treatment and support services. Advancements in medical research and development have brought new behavioral therapies, digital therapeutics, and pharmacological treatments to the market, improving symptom management. Government support through various programs and funding initiatives focused on developmental disorders are enhancing access to early intervention programs, specialized education, and healthcare services. This, in turn, affects the demand for therapeutic treatments. Pharmaceutical and biotechnology companies are actively investing in clinical research to develop novel therapies targeting core and associated symptoms of autism, strengthening the overall market landscape.

Learn more about the FDA-approved drugs for Autism Spectrum Disorder @ Drugs for Autism Spectrum Disorder Treatment

Scope of the Autism Spectrum Disorder Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Forecast Period – 2024-2034
• Autism Spectrum Disorder Companies- Aardvark Therapeutics, Inc., Otsuka Pharmaceutical, H. Lundbeck A/S, Jazz Pharmaceuticals, MapLight Therapeutics, Vanda Pharmaceuticals, ACADIA Pharmaceuticals Inc., AbbVie, Axial Therapeutics, Inc., Hoffmann-La Roche, Yamo Pharmaceuticals LLC, Janssen Pharmaceuticals, Neurim Pharmaceuticals, Flynn Pharma, and others
• Autism Spectrum Disorder Therapies- ML-004, RG7816 (alogabat/RO7017773), AB-2004, L1-79, AJA001, BA-102, CAP-002, radiprodil, RISPERDAL (risperidone), ABILIFY (aripiprazole), SLENYTO (melatonin), and others
• Autism Spectrum Disorder Unmet Needs, KOL’s views, Analyst’s views, Autism Spectrum Disorder Market Access and Reimbursement

Table of Content

1. Key Insights
2. Report Introduction
3. Autism Spectrum Disorder Market Overview at a Glance
4. Autism Spectrum Disorder Epidemiology and Market Methodology
5. Autism Spectrum Disorder Executive Summary
6. Key Events
7. Autism Spectrum Disorder Disease Background and Overview
8. Autism Spectrum Disorder Epidemiology and Patient Population
9. Autism Spectrum Disorder Patient Journey
10. Autism Spectrum Disorder Marketed Products
11. Autism Spectrum Disorder Emerging Treatment and Management
12. Autism Spectrum Disorder: 7 Major Market Analysis
13. Autism Spectrum Disorder SWOT Analysis
14. Autism Spectrum Disorder KOL Views
15. Autism Spectrum Disorder Unmet Needs
16. Autism Spectrum Disorder Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.

Contact Information

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Inclusion Body Myositis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Inclusion Body Myositis, historical and forecasted epidemiology as well as the Inclusion Body Myositis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Inclusion Body Myositis Market with DelveInsight’s In-Depth Report @ Inclusion Body Myositis Market Size

Key Takeaways from the Inclusion Body Myositis Market Report

• The prevalence of IBM is about 5 to 9 cases per million adults, and it varies with factors like geographic area, ethnicity, and age.
• In the US, the estimated number of IBM cases is approximately 20,000 to 25,000.
• IBM usually develops after the age of 50 and is more likely to affect men than women.
• The mean age at symptom onset for patients grouped by presenting symptom was 64.8 years for quadriceps weakness, 62.2 years for finger flexor weakness, and 67.7 years for swallowing difficulties, respectively.
• IBM remains one of the most underrepresented subtypes within idiopathic inflammatory myopathies (IIMs), with rheumatologists citing it as particularly underserved amid increasing calls for faster, safer, and steroid-sparing treatments.
• The leading Inclusion Body Myositis Companies such as Abcuro, and others.
• Promising Inclusion Body Myositis Therapies such as Ulviprubart (ABC008), and others.

Stay ahead in the Inclusion Body Myositis market research with DelveInsight’s Strategic Report @ Inclusion Body Myositis Market Outlook

Inclusion Body Myositis Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of IBM
• Age-specific Cases of IBM
• Gender-specific Cases of IBM

Download the report to understand which factors are driving Inclusion Body Myositis market insight @ Inclusion Body Myositis Prevalence

Marketed Inclusion Body Myositis Therapies 

There are currently no FDA-approved therapies for IBM. Management relies on off-label drugs such as glucocorticoids, methotrexate, cyclophosphamide, azathioprine, intravenous immunoglobulin (IVIG), and alemtuzumab used in clinical practice. However, these off-label drugs offer limited or inconsistent benefit, leading to an unmet need for effective disease-modifying therapies. Management is primarily supportive, focusing on maintaining mobility and function through physical and occupational therapy, preventing falls, and addressing complications such as dysphagia with dietary modifications or swallowing therapy.

Emerging Inclusion Body Myositis Therapies

• Ulviprubart (ABC008): Abcuro Ulviprubart is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing naïve, regulatory, and central memory T cells. Ulviprubart has been designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM). It is being evaluated in Phase II/III of development for the treatment of IBM. In March 2025, Abcuro announced that they had presented safety, pharmacokinetic, and pharmacodynamics data from the Phase I clinical trial evaluating ulviprubart for the treatment of IBM at the American Academy of Neurology (AAN) Annual Meeting. In June 2024, Abcuro announced the completion of enrollment of the registrational Phase II/III MUSCLE clinical trial evaluating ulviprubart for the treatment of IBM.

To know more about Inclusion Body Myositis treatment guidelines, visit @ Inclusion Body Myositis Treatment Market Landscape

Inclusion Body Myositis Therapies and Companies

• Ulviprubart (ABC008): Abcuro

Inclusion Body Myositis Market Dynamics The Inclusion Body Myositis market dynamics have undergone significant changes over the years. IBM remains one of the most underrepresented subtypes within idiopathic inflammatory myopathies, with rheumatologists citing it as particularly underserved. The lack of FDA-approved therapies creates a significant unmet need and opportunity for pharmaceutical companies to develop the first effective disease-modifying treatments. Several late-stage IBM drug programs have been discontinued, including bimagrumab (Novartis) for lack of functional benefit, arimoclomol (Orphazyme) for failing key endpoints, and sirolimus for limited efficacy and substantial side effects. These setbacks have substantially reduced IBM’s pipeline, leaving only a limited number of candidates in development. Current innovation in IBM is focused on targeted immunotherapies like ulviprubart, which aim to slow disease progression, enhance muscle function, and address the limited effectiveness of conventional off-label treatments. The aging population also serves as a driver, as IBM typically affects individuals over 50, creating a growing patient pool for effective therapies.

Learn more about the emerging therapies for Inclusion Body Myositis @ Drugs for Inclusion Body Myositis Treatment

Scope of the Inclusion Body Myositis Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Forecast Period – 2025-2034
• Inclusion Body Myositis Companies- Abcuro, and others
• Inclusion Body Myositis Therapies- Ulviprubart (ABC008), and others
• Inclusion Body Myositis Unmet Needs, KOL’s views, Analyst’s views, Inclusion Body Myositis Market Access and Reimbursement

Table of Content

1. Key Insights
2. Executive Summary of Inclusion Body Myositis
3. Competitive Intelligence Analysis for Inclusion Body Myositis
4. Inclusion Body Myositis: Market Overview at a Glance
5. Inclusion Body Myositis: Disease Background and Overview
6. Patient Journey
7. Inclusion Body Myositis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Inclusion Body Myositis Unmet Needs
10. Key Endpoints of Inclusion Body Myositis Treatment
11. Inclusion Body Myositis Marketed Products
12. Inclusion Body Myositis Emerging Therapies
13. Inclusion Body Myositis: Seven Major Market Analysis
14. Attribute Analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Inclusion Body Myositis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.

Contact Information

Kanishk

kkumar@delveinsight.com

The Major Depressive Disorder market is expanding due to rising prevalence, advances in research, and improved diagnostics. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Major Depressive Disorder market dynamics.

DelveInsight’s “Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the Major Depressive Disorder market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To Know in detail about the Major Depressive Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Major Depressive Disorder Market Forecast

Some of the key facts of the Major Depressive Disorder Market Report

• In September 2025, BrainsWay received US FDA clearance expansion for its Deep Transcranial Magnetic Stimulation (Deep TMS™) system, adding an accelerated protocol for treating major depressive disorder (MDD), including patients with comorbid anxiety symptoms
• In January 2025, the FDA approved Johnson & Johnson’s supplemental New Drug Application for Spravato (esketamine) CIII nasal spray, making it the first and only monotherapy for adults with major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants
• In January 2025, Neumora Therapeutics, Inc. announced results from the Phase 3 KOASTAL-1 Study of navacaprant for treating major depressive disorder (MDD)
• In May 2024, Johnson & Johnson (J&J) reported that seltorexant met all primary and secondary endpoints in its Phase III trial (MDD3001 study) for Major Depressive Disorder
• The Major Depressive Disorder market size is anticipated to grow with a significant CAGR of 4.6% during the study period (2020-2034)
• According to DelveInsight’s estimates, the total Major Depressive Disorder diagnosed prevalent cases in the 7MM were approximately 44 million in 2023
• Major Depressive Disorder has been projected by the World Health Organization to be the leading cause of disease burden in high-income countries by 2032
• Zuranolone, Seltorexant, Navacaprant (NMRA-335140), JNJ-67953964 (Aticaprant), and ALTO-100 are the most anticipated emerging products for the Major Depressive Disorder treatment, that are in the mid or late phase of clinical trials
• Key Major Depressive Disorder Companies: Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Relmada Therapeutics, VistaGen Therapeutics, Intra-Cellular Therapies, Neurocrine Biosciences, Alto Neuroscience, Neumora Therapeutics, Inc., and others
• Key Major Depressive Disorder Therapies: VRAYLAR, AUVELITY, SPRAVATO, REXULTI, FETZIMA, Trintellix, Zuranolone, Seltorexant, Navacaprant, and others
• The Major Depressive Disorder epidemiology based on gender analyzed that in the US, approximately 64% of diagnosed cases were females compared to 36% males in 2023, attributed to factors such as hormonal differences, physiology, and lifestyle factors

Request a sample for the Major Depressive Disorder Market Report

Major Depressive Disorder Overview

Major Depressive Disorder is one of the most prevalent psychiatric disorders characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions. It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts.

Major Depressive Disorder Epidemiology Segmentation

The Major Depressive Disorder market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Major Depressive Disorder
• Gender-specific Diagnosed Prevalent Cases of Major Depressive Disorder
• Severity-specific Diagnosed Prevalent Cases of Major Depressive Disorder

Download the report to understand which factors are driving Major Depressive Disorder epidemiology trends @ Major Depressive Disorder Epidemiological Insights

Major Depressive Disorder Market

The dynamics of the Major Depressive Disorder market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Zuranolone, Seltorexant, Navacaprant, and others during the forecasted period 2020-2034.

Major Depressive Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Major Depressive Disorder market or expected to get launched during the study period. The analysis covers Major Depressive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Major Depressive Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Major Depressive Disorder Therapies and Key Companies

Marketed Therapies:

• VRAYLAR (Cariprazine): AbbVie and Gedeon Richter Plc.
• AUVELITY: Axsome Therapeutics
• SPRAVATO: Johnson & Johnson
• REXULTI: Otsuka Pharmaceuticals
• Trintellix (Vortioxetine): Takeda Pharmaceuticals
• FETZIMA: Forest Laboratories

Emerging Therapies:

• Zuranolone (SAGE-217/BIIB125): Sage Therapeutics/Biogen Inc./Shionogi
• Seltorexant (JNJ42847922): Janssen Pharmaceuticals/Minerva Neurosciences
• Navacaprant (NMRA-335140): Neumora Therapeutics
• ALTO-100: Alto Neuroscience

To know more about Major Depressive Disorder treatment, visit @ Major Depressive Disorder Medications

Major Depressive Disorder Market Drivers

• Rising prevalence of Major Depressive Disorder globally with approximately 44 million diagnosed cases in 7MM
• Advances in research and development of novel therapeutic agents with diverse mechanisms of action
• Improved diagnostics and screening tools leading to earlier detection
• Increased awareness and reduced stigma around mental health conditions
• Growing demand for personalized treatment approaches addressing individual variations in response
• Supportive regulatory environment with Fast Track designations and accelerated approval pathways
• Expanding use of neuromodulation technologies including TMS and tDCS devices

Major Depressive Disorder Market Barriers

• Limited effectiveness of current therapies, with many patients not achieving remission
• Delayed onset of action (often requiring weeks to show benefits) for most antidepressants
• Significant side effects leading to poor patient adherence and treatment discontinuation
• High treatment costs, particularly for novel therapies and device-based interventions
• Challenges in developing personalized treatment strategies due to disease heterogeneity
• Regulatory hurdles, as evidenced by FDA Complete Response Letters for promising candidates
• Competition from established therapeutic classes (SSRIs, SNRIs) making market penetration challenging for novel mechanisms

Scope of the Major Depressive Disorder Market Report

• Coverage: 7MM 
• Study Period: 2020-2034
• Key Major Depressive Disorder Companies: Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Relmada Therapeutics, Alto Neuroscience, Neumora Therapeutics, and others
• Key Major Depressive Disorder Therapies: VRAYLAR, AUVELITY, SPRAVATO, REXULTI, Trintellix, Zuranolone, Seltorexant, Navacaprant, ALTO-100, and others
• Therapeutic Assessment: Major Depressive Disorder current marketed and Major Depressive Disorder emerging therapies
• Major Depressive Disorder Market Dynamics: Major Depressive Disorder market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Major Depressive Disorder Market Access and Reimbursement

Table of Content

1. Key Insights
2. Report Introduction
3. Major Depressive Disorder Market Overview at a Glance
4. Executive Summary of Major Depressive Disorder
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Treatment and Management
8. Organizations Contributing Towards MDD
9. Patient Journey
10. Case Report
11. Marketed Therapies
12. Emerging Therapies
13. Other Assets
14. Discontinued Therapies
15. Major Depressive Disorder (MDD): 7 Major Market Analysis
16. SWOT Analysis
17. Unmet Needs
18. Market Access
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.

Contact Information

Kanishk

kkumar@delveinsight.com

The Gastroparesis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Gastroparesis market dynamics.

DelveInsight’s “Gastroparesis – Market Insights, Epidemiology and Market Forecast – 2036” report offers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

To Know in detail about the Gastroparesis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroparesis Market Forecast https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Some of the key facts of the Gastroparesis Market Report

• The Gastroparesis market size is anticipated to grow with a significant CAGR of approximately 18% during the study period (2022-2036)
• In April 2026, Dr. Falk Pharma GmbH and Renexxion Ireland announced that data from the Global Phase IIb (MOVE-IT) study of naronapride in 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis had been selected for a late-breaking oral presentation at DDW 2026 in the US
• In March 2026, CinDome Pharma announced that enrollment in the Phase II (envisionGI) trial of deudomperidone (CIN-102) for adults with idiopathic gastroparesis had been completed
• In September 2025, CinDome Pharma announced that it had completed enrollment in the (envision3D) Phase II clinical trial of deudomperidone in adults with diabetic gastroparesis
• In June 2025, Processa Pharmaceuticals announced that it had entered into a binding term sheet with Intact Therapeutics, granting Intact an exclusive option to license PCS12852, a best-in-class 5-HT4 receptor agonist with the potential to become a first meaningful treatment for gastroparesis
• Among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of gastroparesis with approximately 724,000 cases in 2025
• Approximately 80% of idiopathic cases are women, as per NORD, demonstrating significant gender bias
• In the US, the highest etiology-specific cases accounted for diabetes (57%), followed by postsurgical cases (15%) and drug-induced cases (11%) in 2025
• Naronapride (ATI-7505), CIN-102 (deudomperidone), NG101 (metopimazine), and PCS12852 (YH12852) are the most anticipated emerging products for the Gastroparesis treatment, that are in the mid or late phase of clinical trials awaiting approval
• Key Gastroparesis Companies: EVOKE Pharma, Renexxion, CinDome Pharma, Neurogastrx, Processa Pharmaceuticals, Intact Therapeutics, and others
• Key Gastroparesis Therapies: Metoclopramide (GIMOTI), Naronapride (ATI-7505), CIN-102 (deudomperidone), NG101 (metopimazine), PCS12852 (YH12852), and others
• The Gastroparesis epidemiology based on gender analyzed that approximately 70% of the diagnosed patients are females, while only 30% are males

Request a sample for the Gastroparesis Market Report: https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Gastroparesis Overview

Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying without any mechanical obstruction. It commonly occurs in people with long-standing diabetes but can also arise from post-surgical complications, medications, or idiopathic causes. Patients typically experience nausea, vomiting, early satiety, bloating, and abdominal pain, which can significantly impact nutrition and quality of life. The condition can lead to complications such as malnutrition, dehydration, and erratic blood glucose levels, particularly in diabetic patients.

Gastroparesis Epidemiology Segmentation

The Gastroparesis market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Gastroparesis
• Etiology-specific Cases of Gastroparesis
• Gender-specific Diagnosed Prevalent Cases of Gastroparesis
• Age-specific Diagnosed Prevalent Cases of Gastroparesis
• Total Cases of Gastroparesis by the Severity of Delayed Gastric Emptying
• Treated cases of Gastroparesis

Download the report to understand which factors are driving Gastroparesis epidemiology trends @ https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Gastroparesis Market

The dynamics of the Gastroparesis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Naronapride (ATI-7505), CIN-102 (deudomperidone), NG101 (metopimazine), and others during the forecasted period 2022-2036.

Gastroparesis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroparesis market or expected to get launched during the study period. The analysis covers Gastroparesis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroparesis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroparesis Therapies and Key Companies

Approved Therapies:

• Metoclopramide (GIMOTI): EVOKE Pharma/EVERSANA

Emerging Therapies:

• Naronapride (ATI-7505): Renexxion
• CIN-102 (deudomperidone): CinDome Pharma
• NG101 (metopimazine): Neurogastrx
• PCS12852 (YH12852): Processa Pharmaceuticals/Intact Therapeutics

To know more about Gastroparesis treatment, visit @ https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Gastroparesis Market Drivers

• Rising prevalence of diabetes globally, with diabetic gastroparesis being the most common subtype
• Aging population more prone to gastrointestinal disorders, including gastroparesis
• Unmet medical needs as current treatments provide limited relief and may have significant side effects
• Advancements in diagnostic capabilities including gastric emptying scintigraphy and wireless motility capsules
• Development of novel prokinetic and antiemetic therapies with improved safety profiles
• Growing disease awareness among clinicians leading to improved diagnosis rates
• Increasing commercial interest in idiopathic and diabetic forms due to higher prevalence

Gastroparesis Market Barriers

• Limited effective treatment options with only one FDA-approved therapy (GIMOTI) specifically indicated for gastroparesis
• Safety concerns with long-term use of metoclopramide including tardive dyskinesia risks and treatment duration limitations
• Insufficient clinical guidelines and standardization across different regions
• High symptom burden and poor quality of life impacting patient adherence
• Potential underdiagnosis, particularly in Asian populations due to lack of research interest
• High cost of approved therapies restricting accessibility
• Need for better biomarkers and diagnostic tools for accurate disease assessment

Scope of the Gastroparesis Market Report

• Coverage: 7MM 
• Study Period: 2022-2036
• Key Gastroparesis Companies: EVOKE Pharma, Renexxion, CinDome Pharma, Neurogastrx, Processa Pharmaceuticals, Intact Therapeutics, and others
• Key Gastroparesis Therapies: Metoclopramide (GIMOTI), Naronapride (ATI-7505), CIN-102 (deudomperidone), NG101 (metopimazine), PCS12852 (YH12852), and others
• Therapeutic Assessment: Gastroparesis current marketed and Gastroparesis emerging therapies
• Gastroparesis Market Dynamics: Gastroparesis market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Gastroparesis Market Access and Reimbursement

Table of Content

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Methodology of Gastroparesis
6. Gastroparesis Market Overview at a Glance
7. Disease Background and Overview of Gastroparesis
8. Epidemiology and Patient Population of Gastroparesis
9. Patient Journey of Gastroparesis
10. Marketed Therapies
11. Emerging Therapies
12. Gastroparesis: Seven Major Market Analysis
13. Unmet Needs of Gastroparesis
14. SWOT Analysis of Gastroparesis
15. KOL Views of Gastroparesis
16. Market Access and Reimbursement of Gastroparesis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm exclusively focused on life sciences. We empower pharmaceutical and biotech companies with robust, end-to-end solutions for enhancing strategic decision-making and performance. Our Healthcare Consulting Services leverage market intelligence to drive growth and resolve challenges with an actionable, practical approach.

Contact Information

Kanishk

kkumar@delveinsight.com